All In Biotech

Drug Trial Radar · NCT01432457

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)

A Phase IV, Multicenter, Randomized, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy of 2 Fixed Doses (50 and 100 mg/Day) of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder

Last checked: Nov 19, 2026Latest source record: Jan 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 924 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

924

Actual

Start

Oct 2011

Primary completion

Jul 2012

Study completion Aug 2012

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 13, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, 8-week study to evaluate the efficacy of 2 doses (50 and 100 mg/day) of desvenlafaxine succinate sustained-release (DVS SR) versus placebo in adult outpatients with major depressive disorder.

Conditions

  • Major Depressive Disorder

Interventions

  • desvenlafaxine succinate sustained-release 50 mg/dayDrug

    50 mg tablets of DVS SR taken orally once daily for 8 weeks; 1 week of placebo taper

  • desvenlafaxine succinate sustained-release 100 mg/dayDrug

    100 mg tablets of DVS SR taken orally once daily for 8 weeks (which includes 1 week of titration at 50 mg/day); 1 week of taper at 50 mg/day

  • placeboDrug

    50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17) at Week 8Time frame: Baseline to Week 8 (final on-therapy)
  2. Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17) at Week 8Time frame: Baseline to Week 8 (final on-therapy)

Locations

61 sites in 1 country. Site status is shown where the registry gives one.

  • Dedicated Clinical Research

    Phoenix, Arizona

  • Deidcated Clinical Research

    Phoenix, Arizona

  • Arkansas Psychiatric Clinic Clinical Research Trials, P.A.

    Little Rock, Arkansas

  • Pacific Clinical Research Medical Group

    Arcadia, California

  • Southwestern Research, Incorporated

    Beverly Hills, California

  • Clinical Innovations, Inc.

    Costa Mesa, California

  • Synergy Clinical Research of Escondido

    Escondido, California

  • Synergy Clinical Research Center

    National City, California

  • Pacific Research Partners

    Oakland, California

  • Pasadena Research Institute, LLC

    Pasadena, California

  • Clinical Innovations, Inc.

    Riverside, California

  • Affiliated Research Institute

    San Diego, California

  • Clinical Innovations, Inc.

    San Diego, California

  • California Neuroscience Research Medical Group, Inc

    Sherman Oaks, California

  • Viking Clinical Research Center

    Temecula, California

  • Collaborative Neuroscience Network, Inc. South Bay

    Torrance, California

  • Pacific Clinical Research Medical Group

    Upland, California

  • Clinical Neuroscience Solutions Incorporated

    Jacksonville, Florida

  • Accurate Clinical Trials, Inc.

    Kissimmee, Florida

  • Florida Clinical Research Center, LLC

    Maitland, Florida

  • Comprehensive NeuroScience, Inc.

    St. Petersburg, Florida

  • Janus Center for Psychiatric Research

    West Palm Beach, Florida

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • Comprehensive NeuroScience, Incorporated

    Atlanta, Georgia

  • Carman Research

    Smyrna, Georgia

  • Joliet Center for Clinical Research

    Joliet, Illinois

  • Capstone Clinical Research

    Libertyville, Illinois

  • AMR-Baber Research Inc.

    Naperville, Illinois

  • American Medical Research, Inc.

    Oak Brook, Illinois

  • Psychiatric Associates

    Overland Park, Kansas

  • Via Christi Research

    Wichita, Kansas

  • Pharmasite Research Inc

    Baltimore, Maryland

  • Midwest Research Group

    Saint Charles, Missouri

  • Heartland Pharma Development

    North Platte, Nebraska

  • CRI Worldwide, LLC

    Marlton, New Jersey

  • Social Psychiatry Research Institute

    Brooklyn, New York

  • Neurobehavioral Research, Inc

    Cedarhurst, New York

  • Eastside Comprehensive Medical Center, LLC

    New York, New York

  • Medical and Behavioral Health Research Pc

    New York, New York

  • Prairie St. Johns Clinic - Fargo

    Fargo, North Dakota

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.